Inc280研究
WebJul 3, 2015 · The objective of this study was to determine the efficacy of a novel, highly potent, orally-bioavailable c-MET inhibitor, INC280, in blocking cell phenotypes important … WebCapmatinib (INCB28060, INC280, NVP-INC280) is a novel, ATP-competitive inhibitor of c-MET with IC50 of 0.13 nM in a cell-free assay, inactive against RONβ, as well as EGFR and HER-3. Capmatinib (INCB28060) inhibits Wnt/β-catenin and EMT signaling pathways and induces apoptosis in diffuse gastric cancer positive for c-MET amplification. Phase 1.
Inc280研究
Did you know?
WebDec 18, 2024 · 研究药物卡马替尼(也称为 INC280)是一种口服药物,被称为“靶向”药物,这意味着它针对癌细胞中可能无法正常工作的特定过程(称为失调)。 NSCLC 患者癌细胞中 MET 信号的失调被认为会使癌症恶化。 Capmatinib 已被证明可以选择性地阻断 MET 基因的 … WebJun 11, 2015 · The purpose of this study was to determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) of INC280 in combination with erlotinib in the Phase Ib of this study, and to assess the anti-tumor activity and safety of INC280 alone, and in combination with erlotinib, versus platinum with pemetrexed in the Phase II of this …
WebMar 31, 2024 · 总的来说,本研究中在MET高肿瘤患者中观察到的抗肿瘤活性表明,本研究中应用的严格的生物标志物选择标准是成功治疗HCC患者使用MET单药抑制剂治疗的必要条件。卡马替尼 (INC280) 代表了一种有前景的策略,用于适当选择的晚期met高HCC患者的抗met治疗。微信扫描 ... WebMar 20, 2015 · Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR -mutated (mut), MET-positive NSCLC: A single-arm phase lb/ll study.
WebJun 10, 2024 · 因此,2010年我们提出了第一个研究思路,考虑可以把c-met抑制剂inc280和吉非替尼两药联合起来以克服耐药。 在此思路下,我们开始了一系列临床I期、II期研究,就是非常有名的INC280联合吉非替治疗c-MET扩增肺癌患者的有效性及安全性研究。 Web临床研究实验室 ... Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy. 转移性结直肠癌 Squamous Cell Carcinoma of Head and Neck (SCCHN) ...
http://www.leirenbang.com/zx/2024/0408/245002.html
WebAnalog Embedded processing Semiconductor company TI.com durgesh catfishWebMay 26, 2024 · 9004 Background: Capmatinib is a highly potent and selective MET inhibitor. Previous data of GEOMETRY mono-1 study showed a clinically meaningful overall response rate (ORR) and manageable toxicity profile in patients (pts) with METΔex14–mutated NSCLC who received 1–2 prior lines of treatment (tx) (Cohort 4) and in particular a high ORR in tx … cryptococcus diarrheahttp://www.changbaicao.cn/trialsdetail-id-12013.html durga weaponshttp://www.chicopharm.cn/new_detail/id/159.html durgesh chaudharyWebJul 3, 2015 · The persistent inhibitory effect of INC280, is consistent with studies reported by Liu et al., who demonstrated that a single dose of INC280 in vivo resulted in 90% inhibition of c-MET ... durga which mythWebJul 3, 2015 · The objective of this study was to determine the efficacy of a novel, highly potent, orally-bioavailable c-MET inhibitor, INC280, in blocking cell phenotypes important … cryptococcus encephalitisWebAug 20, 2024 · 卡马替尼( inc280 )是一种高效的、选择性的 met 抑制剂,已知可以穿过 bbb,并且先前已经报道了卡马替尼(inc280)的颅内活性。 此处介绍了 … durgesh chopra